Blog

Did you foresee this £12M cost increase coming?

October sees World Mental Health Day marked and recognised across the globe. The overall objective of the day is to raise awareness of mental health issues and mobilise efforts in support of better mental health. This year’s focus? Mental health in the workplace.

Globally, the WHO reports, “more than 300 million people suffer from depression, the leading cause of disability. More than 260 million are living with anxiety disorders. Many of these people live with both.

The rising costs of mental health disorders

A recent WHO-led study estimates that depression and anxiety disorders cost the global economy US$ 1 trillion each year in lost productivity.” That’s no small sum.

The Guardian reports that 2016 saw the NHS prescribing “a record number of antidepressants, fuelling an upward trend that has seen the number of pills given to patients more than double over the last decade.” (The Guardian)

To demonstrate this, our analysis of the current tariff increase – due to temporary supply issues – of the generic antipsychotic drug Quetiapine (IR) in the UK, shows just how volatile the NHS’s bill for mental health can be.

Quetiapine (IR) in the UK

At-a-glance MarketView analytics

Our interrogative analytics of NHS GP Prescribing Data reveals that the monthly cost to the NHS of Quetiapine (IR)s has risen by over £12M per month in June and July. This ‘temporary’ price concession is still in place now, so the 5 months to October will result in a £50M+ extraordinary cost to the NHS, from just one drug. To put this in context the cost of protecting the whole country from flu with the ‘flu jab’ – costs the NHS around £100M per year.

Inspiremed’s rapid-fire analysis provides valuable insights from NHS and IMS prescription data at the touch of a button. And presents findings in clear easy-to-analyse visualisation dashboards like the one we picture here.

Drill down to key data sets, remove the complexities of data analysis and drive effective sales and marketing activities with real time data.

Book my demonstration

“Working with Inspiremed is a great partnership experience and they make sure they understand your business, the industry that you are in and what you want to achieve in the use of the product.”

National Sales Manager, UK Pharmaceutical Company

“Fantastic customer service, any requests from us to fine tune the functionality or appearance of the product is done in most cases on the same day as the request.”

National Sales Manager, UK Pharmaceutical Company

“We are working in an ever evolving industry where data increasingly drives marketing and sales activity. I believe RX Analyser is the most comprehensive analytics tool available for prescription data analysis. I can already see other business areas (within my company) that could really benefit.”

Sales and Marketing Manager, Leading Healthcare Company, 2016

“The feature I like most? The ability to drill down to competitor sales.”

Senior Manager, Global Healthcare Company, 2016

“Inspiremed are a pleasure to work with, blending both a solid understanding of software development and commercial experience.”

Sales and Marketing Manager, Leading Healthcare Company, 2016

“I am extremely happy with the model and with the working relationship we have with Inspiremed.”

Country Manager UK, Leading Diagnostics Company

Sign up for added insights